China Medical System Holdings Limited (CHSYF) Research

China Medical System Holdings Limited functions as an investment holding enterprise with a primary focus on the pharmaceutical sector within the People's Republic of China. The company's core activities involve the development, marketing, and distribution of a comprehensive range of pharmaceutical products. Its diverse portfolio addresses a wide array of medical conditions, offering treatments for cardiovascular issues (such as Plendil for hypertension and Imdur for heart disease), mental health disorders (including Deanxit for depression and anxiety), and various gastrointestinal ailments (like Ursofalk for gallstones and Salofalk for inflammatory bowel conditions). Furthermore, its therapeutic range extends to solutions for acute heart failure (XinHuoSu), numerous infections (e.g., DanShenTong capsules), respiratory illnesses (YiNuoShu), liver cancer (Ganfule capsules), osteoporosis (Elcatonin injection), and dermatological fungal conditions (Lamisil tablets), among many others. Beyond its principal pharmaceutical operations, the company also maintains interests in agriculture and livestock. Established in 1995, China Medical System Holdings Limited is based in North Point, Hong Kong, and operates as a subsidiary of Treasure Sea Limited.

Open China Medical System Holdings Limited (CHSYF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.